The US Food and Drug Administration has approval of Dengvaxia, the first vaccine to be approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people, aged from 9 to 16, who have laboratory-confirmed previous dengue infection and who reside in endemic areas.
“Dengue disease is the most common mosquito-borne viral disease in the world and global incidence has increased in recent decades. The FDA is committed to working proactively with our partners at the US Centres for Disease Control and Prevention, as well as international partners, including the World Health Organization, to combat public health threats, including through facilitating the development and availability of medical products to address emerging infectious diseases. While there is no cure for dengue disease, this approval is an important step toward helping to reduce the impact of this virus in endemic regions of the United States.”
The CDC estimates that more than one-third of the world’s population is living in areas at risk of infection by dengue virus which causes dengue fever, a leading cause of illness among people living in the tropics and subtropics. The first infection with dengue virus typically results in either no symptoms or a mild illness that can be mistaken for the flu or another viral infection. A subsequent infection can lead to severe dengue, including dengue haemorrhagic fever (DHF), a more severe form of the disease that can be fatal. Symptoms may include stomach pain, persistent vomiting, bleeding, confusion and difficulty breathing.